Surgical Science Sweden AB (publ) announced on July 28, 2021 that a conditional agreement to acquire all shares outstanding of Simbionix USA Corp. (“Simbionix”) had been entered into. Simbionix works with simulation for training of surgeons and other medical specialists within a broad number of areas, such as for robotic surgery. The company has approximately 120 employees, of which approximately 100 employees are based in Israel and approximately 20 are based in the US.
Surgical Science Sweden AB (publ) today, after all conditions precedent have been fulfilled, has completed the acquisition of all shares of Simbionix USA Corp. and the subsidiary Simbionix, Ltd and thus controls 100% of the shares in the two companies. Both companies will be consolidated into Surgical Science upon closing of the acquisition.
Please refer to press releases dated July 28 and 29 and August 16, 2021 for further details.
Gothenburg, Sweden, August 24, 2021
Surgical Science Sweden AB (publ)
The press release is available in the attachment or via
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.